Beth Israel Deaconess Medical Center, a Framingham biotechnology company, and an international research group are joining in a research initiative aimed at improving the diagnosis and treatment for one of the deadliest forms of cancer. James Moser, associate professor of surgery at Beth Israel Deaconess Medical Center, is quoted.
Trending News
Research Provides Clues to Spleen’s Role in Coronary Artery Disease
Genetic variants may drive visible changes in the spleen that contribute to heart disease
Patient Who Received Pig Kidney Becomes First To Progress to Human Kidney Transplant
Study shows xenotransplantation can serve as a bridge for patients with end-stage kidney disease
Pilots, Flight Attendants Have Greater Risk of Radiation-Related Cancer Death Than Other Professions
Findings support efforts to protect U.S. aircrews from cosmic radiation exposure